PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
Joseph M. Gozgit, Melissa M. Vasbinder, Ryan Abo, Kaiko Kunii, Kristy Kuplast‐Barr, Bin Gui, Alvin Lu, Jennifer R. Molina, Elena Minissale, Kerren K. Swinger, Tim J. Wigle, Danielle J. Blackwell, Christina R. Majer, Yue Ren, Mario Niepel, Zacharenia A. Varsamis, Sunaina Nayak, Ellen Bamberg, Jan-Rung Mo, W. David Church, Ahmed S.A. Mady, Jeff Song, Luke Utley, Patricia E. Rao, Timothy J. Mitchison, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack
Topics & Concepts
Immune systemBiologyInterferonCancer cellCancer researchSignal transductionAcquired immune systemCancerImmunityNucleic acidCell signalingCancer immunotherapyImmunotherapyCell biologyImmunologyBiochemistryGeneticsPARP inhibition in cancer therapyinterferon and immune responsesCancer Immunotherapy and Biomarkers